Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands to 41%. Fiscal year guidance was raised, and William Blair sees continued growth momentum. Analysts reaffirm Outperform ratings.
– Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 –
– Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23 – Increased FY 2024 revenue.
In this article, we will take a detailed look at the 15 Stocks That Will Outperform the S&P 500 in 2024. For a quick overview of such stocks, read our article 5 Stocks That Will Outperform the S&P 500 in 2024. All indicators show that the US economy remains resilient and in a much better shape than expected, […]